immunotherapy - search results

H&E-stained tumor tissue on microscopy slides can predict which patients with metastatic clear cell renal cell carcinoma (mccRCC) are most likely to respond to immunotherapy, with the prediction further refined by adding PBRM1 mutation status, research suggests.

Scientists have developed a new technology for immunotherapy that isolates T cells from the blood instead of tumor tissue.

University of Pittsburgh researchers have detailed how probiotic bacteria travel from the gut to cancer tumors and then stimulate immune cells to make immunotherapy more effective.

In this Inside Precision Medicine webinar, our distinguished guest speaker, Dr. Scott Tomlins, described the development, validation, and clinical utility of a new pan-tumor predictive biomarker for immunotherapy benefit: Immunotherapy Response Score^™ (IRS).

Using a chemical blocker stops CD8+ T cells from migrating out of skin cancer cells. Together with immunotherapy, this new approach could boost the efficacy of immunotherapy.

CD5+ cells could be an important marker for response to immunotherapy for melanoma and other cancers, according to new research from the Washington University School of Medicine. 

Bacteria naturally found in the lungs help create an environment that suppresses T-cell activation in the lymph nodes near the lungs—a finding that could explain why immunotherapy for lung cancer often fails.

New evidence from researchers at the Johns Hopkins Kimmel Cancer Center has found that a subset of mutations within the TMB—defined at “persistent mutations"—are less likely than others to be edited out, making them always visible to the immune system which results in them being more likely to respond to immunotherapies.

L-fucose, a nontoxic dietary plant sugar that is enriched in red and brown seaweeds, can increase TILs, promote antitumor immunity, and improve the efficacy of immunotherapy.

Using immune checkpoint inhibitors prior to surgery of patients with localized mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC) is an effective approach to treating the disease